Inhibitory Effect of High Concentration Insulin on the Proliferation of Human Leukemia Cell Strain K562
Abstract
To study the impact of high concentration insulin on the proliferation and apoptosis of K562 cell strain. Methods K562 cells were treated with different concentrations of insulin. The proliferation activity was tested by CCK-8 assay, cytometry, and trypan blue exclusion. The alterations in glucose concentration of the culture media were monitored while the apoptosis of K562 cells was detected by flow cytometry. The effects of high concentration insulin on the proliferation of K562 cells were inhibited by varying concentrations of insulin-like growth factor-1 (IGF-1) and Suramin. Results Under the range of concentration (0.1-1 mU/mL), insulin facilitated the proliferation of K562 cells. In contrast, insulin at high concentrations (1.6-100 mU/mL) had the opposite effect, in a dose- and time-dependent manner. Different concentrations of glucose in the culture medium had no significant influence on the inhibitory effect of high concentration insulin on the proliferation of human leukemia cell strain K562. At low concentration insulin inhibited the apoptosis of K562 cells, in a dose-dependent manner. In contrast, insulin at high concentration had the opposite effect, in a dose-dependent manner. Furthermore, IGF-1 reversed the inhibitory effect of high concentration insulin on the proliferation of K562 cell in a dose- and time-dependent manner. Suramin, which is an IGF-1 receptor non-specific blocker, had the opposite effect on K562 cells, also in a dose- and time-dependent manner. Conclusion These results indicate insulin has a dual effect on K562 cells. The dual effect is probably mediated by the binding of insulin and IGF-1R. Inhibitory effect of high concentration insulin on the proliferation of K562 cells is unrelated with the glucose metabolism in the culture media.
Keywords: Insulin, Leukemia cell Inhibitory effect of proliferation, High concentration Insulin-like growth factor-1
Full Text:
PDFReferences
LANN D. LEROITH D. The role of endocrine insulin-like growth factor-I and insulin in breast cancer. J Mammary Gland Biol Neoplasia,2008,13(4) :371-379
WOLPIN BM. MICHAUD DS, GIOVANNUCCI EL, et al. Circulating insulin-like growth factor binding protein-1 and the risk of pancreatic cancer. Cancer Res,2007,67( 16) ;7923- 7928.
LEIBIGER B, MOEDE T, UHLES S, et al. Insulin- feedback via PI3K-C2alpha activated PKBalpha/Aktl is required for glucose-stimulated insulin secretion. FASEB J, 2010,24(6):1824-1837.
HUANG SS, LEAL SM, CHEN CL, et al. Identification of insulin receptor substrate proteins as key molecules for the TbetaR-V/LRP-l-mediated growth inhibitory signaling cascade in epithelial and myeloid cells. FASEB J, 2004, 18 (14): 1719-1721.
FRESNO VJA, CASADO E, DE CASTRO J, et al. Р13К/ Akt signalling pathway and cancer. Cancer Treat Rev,2004, 30(2): 193-204.
VAZQUEZ-MARTIN A, OLIVER AS-FERRAROS C, CUFI S, et al. Metformin and energy metabolism in breast cancer; from insulin physiology to tumour-initiating stem cells. Curr Mol Med,2010,10(7);674-691.
ZHANG G, LI X, ZHANG L. et al. The expression and role of hybrid insulin insulin-like growth factor receptor type 1 in endometrial carcinoma cells. Cancer Genet Cytogenet, 2010,200(2): 140-148.
ADACHI Y, YAMAMOTO H, OHASHI H, et al. A candidate targeting molecule of insulin-like growth factor- I receptor for gastrointestinal cancers. World J Gastroenterol. 2010,16(46);5779-5789.
SCHEEN AJ, LEFEBVRE PJ. Insulin glargine and cancer; a storm in a glass of water? Rev Med Liege,2009 ,64(9) :440- 445.
AUMILLER J. Relationship between diabetology and oncology. Cancer alarm initially without practical consequences. MMW Fortschr Med.2009,151(42): 16.
LOU J, CHU G, ZHOU G, et al. Comparison between two kinds of cigarette smoke condensates ( CSCs ) of the cytogenotoxicity and protein expression in a human B-cell lymphoblastoid cell line using CCK-8 assay, comet assay and protein microarray. Mutat Res,2010,697(1/2) ;55-59.
MUMBA ND, MENTEN J, PYANA PP, et al. Stage determination in sleeping sickness; comparison of two cell counting and two parasite detection techniques. Trop Med Int Health.2013,18(6) :778-782.
HUMPEA, BECK C SCHOCH R. et al. Establishment and optimization of a flow cytometric method for evaluation of viability of CD34+ cells after cryopreservation and comparison with trypan blue exclusion staining. Transfusion, 2005,45(7);1208-1213.
MAYLE A. LUO M. JEONG M. et al. Flow cytometry analysis of murine hematopoietic stem cells. Cytometry A, 2013,83(1):27-37.
CHENALJ, PIERRE K. PELLERIN L. Insulin and IGF-1 enhance the expression of the neuronal monocarboxylate transporter MCT2 by translational activation via stimulation of the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin pathway. Eur J Neurosci,2008,27( 1);53-65.
WAHNER HAE. HALUSKA P, SCHNEIDER PA, et al. Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitro. Cancer Res,2009,69(19):7635-7643.
NAVENOT JM. FUJII N, PEIPER SC. KiSSl metastasis suppressor gene product induces suppression of tyrosine kinase receptor signaling to Akt, tumor necrosis factor family ligand expression, and apoptosis. Mol Pharmacol• 2009, 75 (5):1074-1083.
MIRSHAHI P. RAFII A, VINCENT U et al. Vasculogenic mimicry of acute leukemic bone marrow stromal cells. Leukemia, 2009,23(6): 1039-104 8.
BACK K. BRANNMARK C, STRALFORS P. et al. Differential effects of IGF- I , IGF- Ц and insulin in human preadipocytes and adipocytes—role of insulin and IGF- 1 receptors. Mol Cell Endocrinol»2011 ,339( 1/2) : 130-135.
DENLEY A, CARROLL JM, BRIERLEY GV, et al. Differential activation of insulin receptor substrates 1 and 2 by insulin-like growth factor-activated insulin receptors. Mol Cell Biol,2007,27( 10):3569-3577.
MENG I), SHI X, JIANG BH, et al. Insulin-like growth factor- I (IGF- I ) induces epidermal growth factor receptor transactivation and cell proliferation through reactive oxygen species. Free Radic Biol Med,2007,42( 11); 1651-1660.
SURINYA KH, FORBES BE, OCCHIODORO F. et al. An investigation of the ligand binding properties and negative cooperativity of soluble insulin-like growth factor receptors. J Biol Chem.2008,283(9) ;5355-5363.
GUBBELS JA. CLAUSSEN N. KAPUR AK. et al. The detection, treatment* and biology of epithelial ovarian cancer. J Ovarian Res,2010(3) ;8. doi;10. 1186/1757-2215-3-
HAN LY, KIPPS E. KAYE SB. Current treatment and clinical trials in ovarian cancer. Expert Opin Investigl Drugs. 2010,19(4):521-534.
MOSS С, KAYE SB. Ovarian cancer; progress and continuing controversies in management. Eur J Cancer.2002. 38(13):1701-1707.
ROSELL R. LORD RV, TARON M,et al. DNA repair and cisplatin resistance in non-small-cell lungcancer. Lung Cancer. 2002.38( 3): 217-227.
JORDAN P.CARMO-FONSECA M. Molecular mechanisms involved in cisplatin cytotoxicity. Cell Mol Life Sci,2000;57 (8-9):1229-1235.
BERNSTEIN C. BERNSTEIN H. PAYNE CM.dat. DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways; fail-safe protection against carcinogenesis. Mutat Res.2002,511(2): 145-178.
LENGAUER C. KINZLER KW. VOGELSTEIN B. Genetic instabilities in human cancers. Nature,1998,396(6712):643- 649.
ABRAHAM RT. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev, 2001, 15 ( 17 ): 2177- 2196.
CRISTIANO BE, CHAN JC, HANNAN KM, et al. A specific role for AKT3 in the genesis of ovarian cancer through modulation of G(2)-M phase transition. Cancer Res, 2006,66(24):11718-11725.
HELLEDAY T. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol.2011,5(4);387-393.
SNYDER AR, ZHOU J, DENG Z, et al. Therapeutic doses of hydroxyurea cause telomere dysfunction and reduce trf2 binding to telomeres. Cancer Biol Ther, 2009, 8 ( 12): 1136- 1145.
CREGAN SP, DAWSON VL, SLACK RS. Role of AIF in caspase-dependent and caspase independent cell death. Oncogene,2004,23(16):2785-2796.
Refbacks
- There are currently no refbacks.
